JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

Prior treatment

• Patients who have previously been treated with KRAS G12C inhibitors, KRAS G12D inhibitors, pan-RAS/pan-KRAS/multi-KRAS inhibitors, or similar agents.

Other illness

• Inability to swallow oral medications, or presence of gastrointestinal dysfunction or gastrointestinal disorders that may significantly alter the absorption of the study drug.
• Known serious allergy to JAB-23E73 or excipient.

Lab values

• Participants who have previously been treated with cetuximab or other EGFR antibodies (Part B1 only).
• QT interval\>470 msec.
• LVEF ≤50% assessed by ECHO or MUGA.

Other

• Patients with primary central nervous system tumors.
• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures or medical intervention.

• Written informed consent.
• Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).
• Histologically or cytologically confirmed locally advanced or metastatic solid tumors that are not suitable for curative interventions and who have received relevant prior systemic therapy.(Part A)
• Histologically/cytologically confirmed unresectable locally advanced or metastatic CRC who progressed on or were intolerant to ≥1 standard systemic regimen with fluorouracil derivatives, oxaliplatin, irinotecan, FDA-approved immunotherapy or targeted therapies.(Part B1 only)
• Patients must have KRAS alterations.
• Participants are required to provide an archived tumor sample.
• Patients with a life expectancy ≥3 months.
• ECOG performance status score of 0 or 1.
• Patients must have at least one measurable lesion as defined by RECIST v1.1.